Ossendorp F - Search Results

1

CD4⁺ T Cell and NK Cell Interplay Key to Regression of MHC Class I^low Tumors upon TLR7/8 Agonist Therapy.

Doorduijn EM, Sluijter M, Salvatori DC, Silvestri S, Maas S, Arens R, Ossendorp F, van der Burg SH, van Hall T. Doorduijn EM, et al. Among authors: ossendorp f. Cancer Immunol Res. 2017 Aug;5(8):642-653. doi: 10.1158/2326-6066.CIR-16-0334. Epub 2017 Jun 21. Cancer Immunol Res. 2017. PMID: 28637878

2

Abrogation of CTL epitope processing by single amino acid substitution flanking the C-terminal proteasome cleavage site.

Beekman NJ, van Veelen PA, van Hall T, Neisig A, Sijts A, Camps M, Kloetzel PM, Neefjes JJ, Melief CJ, Ossendorp F. Beekman NJ, et al. Among authors: ossendorp f. J Immunol. 2000 Feb 15;164(4):1898-905. doi: 10.4049/jimmunol.164.4.1898. J Immunol. 2000. PMID: 10657639

3

Identification of a novel tumor-specific CTL epitope presented by RMA, EL-4, and MBL-2 lymphomas reveals their common origin.

van Hall T, van Bergen J, van Veelen PA, Kraakman M, Heukamp LC, Koning F, Melief CJ, Ossendorp F, Offringa R. van Hall T, et al. Among authors: ossendorp f. J Immunol. 2000 Jul 15;165(2):869-77. doi: 10.4049/jimmunol.165.2.869. J Immunol. 2000. PMID: 10878361

4

Strategies for immunotherapy of cancer.

Melief CJ, Toes RE, Medema JP, van der Burg SH, Ossendorp F, Offringa R. Melief CJ, et al. Among authors: ossendorp f. Adv Immunol. 2000;75:235-82. doi: 10.1016/s0065-2776(00)75006-1. Adv Immunol. 2000. PMID: 10879286 Review. No abstract available.

5

Importance of CD4(+) T helper cell responses in tumor immunity.

Ossendorp F, Toes RE, Offringa R, van der Burg SH, Melief CJ. Ossendorp F, et al. Immunol Lett. 2000 Sep 15;74(1):75-9. doi: 10.1016/s0165-2478(00)00252-2. Immunol Lett. 2000. PMID: 10996631 Review. No abstract available.

6

Design and evaluation of antigen-specific vaccination strategies against cancer.

Offringa R, van der Burg SH, Ossendorp F, Toes RE, Melief CJ. Offringa R, et al. Among authors: ossendorp f. Curr Opin Immunol. 2000 Oct;12(5):576-82. doi: 10.1016/s0952-7915(00)00145-x. Curr Opin Immunol. 2000. PMID: 11007362 Review.

7

Superior tumor protection induced by a cellular vaccine carrying a tumor-specific T helper epitope by genetic exchange of the class II-associated invariant chain peptide.

van Bergen J, Camps M, Offringa R, Melief CJ, Ossendorp F, Koning F. van Bergen J, et al. Among authors: ossendorp f. Cancer Res. 2000 Nov 15;60(22):6427-33. Cancer Res. 2000. PMID: 11103809

8

Effective immunotherapy of cancer in MUC1-transgenic mice using clonal cytotoxic T lymphocytes directed against an immunodominant MUC1 epitope.

Heukamp LC, van Hall T, Ossendorp F, Burchell JM, Melief CJ, Taylor-Papadimitriou J, Offringa R. Heukamp LC, et al. Among authors: ossendorp f. J Immunother. 2002 Jan-Feb;25(1):46-56. doi: 10.1097/00002371-200201000-00005. J Immunother. 2002. PMID: 11926165

9

Differential kinetics of antigen-specific CD4+ and CD8+ T cell responses in the regression of retrovirus-induced sarcomas.

Schepers K, Toebes M, Sotthewes G, Vyth-Dreese FA, Dellemijn TA, Melief CJ, Ossendorp F, Schumacher TN. Schepers K, et al. Among authors: ossendorp f. J Immunol. 2002 Sep 15;169(6):3191-9. doi: 10.4049/jimmunol.169.6.3191. J Immunol. 2002. PMID: 12218137

10

Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells.

Zwaveling S, Vierboom MP, Ferreira Mota SC, Hendriks JA, Ooms ME, Sutmuller RP, Franken KL, Nijman HW, Ossendorp F, Van Der Burg SH, Offringa R, Melief CJ. Zwaveling S, et al. Among authors: ossendorp f. Cancer Res. 2002 Nov 1;62(21):6187-93. Cancer Res. 2002. PMID: 12414646

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

218 results

Search Page